Eilaf Pharma has entered into an agreement to distribute Saladax Biomedical's My5-FU test in Egypt and throughout the Middle East North African (MENA) region.
My5-FU test is designed to measure levels of an anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients.
The test facilitates oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects.
Saladax senior vice president and chief marketing officer Adrienne Choma said, "We’re happy to be working with Eilaf to provide patients with colorectal cancer in the region a new option to help maximize the therapeutic effect of their chemotherapy."
Eilaf Pharma managing director Haytham Abuelfadl said, "We hope that with this tool, our oncologists will be able to provide their patients with the most appropriate course of chemotherapy possible."